Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.4100 (0.37%) ($5.2400 - $5.4900) on Tue. Nov. 12, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.65% (three month average) | RSI | 85 | Latest Price | $5.4100(0.37%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 4.5% a day on average for past five trading days. | Weekly Trend | ADMS advances 15.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) VCSH(19%) CEMB(16%) FXI(13%) KWEB(13%) SLV(13%) | Factors Impacting ADMS price | ADMS will decline at least -2.825% in a week (0% probabilities). UUP(-12%) QQQ(-9%) XLK(-8%) XLC(-7%) VUG(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.825% (StdDev 5.65%) | Hourly BBV | 0 () | Intraday Trend | 0.6% | | | |
|
5 Day Moving Average | $5.12(5.66%) | 10 Day Moving Average | $4.7(15.11%) | 20 Day Moving Average | $4.34(24.65%) | To recent high | -27.5% | To recent low | 5.7% | Market Cap | $153m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |